--- title: "Biotech startup Earendil Labs is reported to raise HKD 3.9 billion through a Hong Kong IPO for AI drug development, collaborating with Sanofi and WuXi AppTec" type: "News" locale: "en" url: "https://longbridge.com/en/news/279104596.md" description: "Biotechnology startup Earendil Labs plans to go public in Hong Kong, aiming to raise up to $500 million (approximately HKD 3.9 billion). The company has partnerships with well-known pharmaceutical companies such as Sanofi and WuXi Biologics. Meanwhile, integrated circuit design company Guomin Technology and network solutions provider Feisuke Innovation have also begun their initial public offerings, planning to raise HKD 1.03 billion and HKD 1.66 billion, respectively, with strong oversubscription performance on their first day" datetime: "2026-03-14T01:35:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279104596.md) - [en](https://longbridge.com/en/news/279104596.md) - [zh-HK](https://longbridge.com/zh-HK/news/279104596.md) --- # Biotech startup Earendil Labs is reported to raise HKD 3.9 billion through a Hong Kong IPO for AI drug development, collaborating with Sanofi and WuXi AppTec According to foreign media reports, biotechnology startup Earendil Labs is reportedly planning to go public in Hong Kong, raising up to $500 million, equivalent to HKD 3.9 billion. Two new stocks began their subscription yesterday, with integrated circuit design company Guomin Technology (2701) raising a maximum of HKD 1.03 billion, oversubscribed by 4.1 times on the first day. Network solutions provider Feisuk Innovation (3355) aims to raise up to HKD 1.66 billion, with a strong first-day subscription performance recording an oversubscription of 31.4 times. Bloomberg cited sources reporting that Earendil Labs, which develops drugs using AI technology, is considering listing in Hong Kong, with the listing plan arranged by China International Capital Corporation and Morgan Stanley. Earendil Labs has partnerships with several well-known pharmaceutical companies, including France's Sanofi and WuXi Biologics (2269). ## Feisuk Innovation Entry Fee HKD 4,201.96 As for the new stocks that started subscription yesterday, Feisuk Innovation plans to issue 40 million H shares, with 10% available for public offering in Hong Kong, and the subscription price ranging from HKD 35.2 to HKD 41.6, raising a maximum of HKD 1.66 billion. As of last night, Feisuk Innovation received HKD 5.383 billion in margin subscriptions, with the public offering subscription amounting to HKD 166 million, equivalent to an oversubscription of 31.4 times. The company has a board lot of 100 shares, with an entry fee of HKD 4,201.96, and will be listed on the 23rd of this month, with China International Capital Corporation, CITIC Securities International, and China Merchants Securities International as joint sponsors. ## Guomin Technology Oversubscribed 4.1 Times on First Day Guomin Technology plans to issue 95 million H shares, with 10% available for public offering in Hong Kong, and a maximum offering price of HKD 10.8, raising up to HKD 1.03 billion. As of last night, Guomin Technology received HKD 529 million in margin subscriptions, with the public offering raising HKD 103 million, oversubscribed by 4.1 times. The company has a board lot of 200 shares, with an entry fee of HKD 2,181.78, and will also be listed on the 23rd of this month, with CITIC Securities as the sole sponsor. In addition, silicon carbide epitaxial chip manufacturer Hantian Tiancheng has passed the listing hearing, with China International Capital Corporation as the sole sponsor ### Related Stocks - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [520500.CN](https://longbridge.com/en/quote/520500.CN.md) - [02269.HK](https://longbridge.com/en/quote/02269.HK.md) - [562050.CN](https://longbridge.com/en/quote/562050.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [02359.HK](https://longbridge.com/en/quote/02359.HK.md) - [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md) - [SNY.US](https://longbridge.com/en/quote/SNY.US.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [603259.CN](https://longbridge.com/en/quote/603259.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [688108.CN](https://longbridge.com/en/quote/688108.CN.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [688480.CN](https://longbridge.com/en/quote/688480.CN.md) ## Related News & Research - [A Look At WuXi Biologics (SEHK:2269) Valuation After Securing ISO 13485:2016 Certification](https://longbridge.com/en/news/283038681.md) - [Faron raises EUR 40.1 million in rights issue to advance cancer drug bexmarilimab](https://longbridge.com/en/news/282233028.md) - [Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002](https://longbridge.com/en/news/282660503.md) - [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md) - [AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid](https://longbridge.com/en/news/282533515.md)